# Layer 3 -- Eval Questions Spec

> Format: all `multi_choice`, 8-10 options per round, n-of-many (agent determines how many to select).
> Scoring: agent uses `\bbox{A,C,F}` format; exact set match against answer.
> All question text and option text must be in English.
> 12 rounds covering MS-R, MS-I, DU-R, DU-I, P-R, P-I, MD-R, MD-I, DP-I, MP-I, MDP-I, MDP-I.

---

## 1. Round Inventory

| Round | Question Type | Tags | Main Skill Tested | Depends on Update? | Cross-round Reversal? |
|---|---|---|---|---|---|
| r1 | multi_choice | MS-R | Technical specification synthesis -- both vendors meet requirements (C3, non-conflict) | No | No |
| r2 | multi_choice | MS-I | Grant conditions inference -- "no strings" vs procurement preference obligation (C1 partial) | No | Yes (R2->R5 seed) |
| r3 | multi_choice | MS-R | Clinical evaluation baseline -- Brown's evaluation and methodology question (C2 partial) | No | Yes (R3->R6 seed) |
| r4 | multi_choice | MS-I | CFO position analysis -- Phase 1 support and information basis (C4 partial) | No | Yes (R4->R10 seed) |
| r5 | multi_choice | DU-R | Grant conditions reversal after grant_agreement_cardiopharma.md (C1 full reversal) | Yes (Update 1) | Yes (R2->R5 via C1) |
| r6 | multi_choice | DU-I | Clinical evaluation reversal after yun_eval_note.md (C2 full reversal) | Yes (Update 2) | Yes (R3->R6 via C2) |
| r7 | multi_choice | P-R | User preference identification (structured options + explicit tradeoffs) | No | No |
| r8 | multi_choice | MD-R | Maintenance contract analysis after maintenance_contract_vendora.md (Update 3) | Yes (Update 3) | No |
| r9 | multi_choice | P-I | Generate procurement recommendation in user's preferred format (structured options with tradeoffs) | No | No |
| r10 | multi_choice | DP-I | CFO reversal analysis -- rational updating vs inconsistency (C4 full reversal) | Yes (Update 3) | Yes (R4->R10 via C4) |
| r11 | multi_choice | MP-I | Conflict analysis -- grant compliance + corrected clinical + contract gaps (multi-factor) | No | No |
| r12 | multi_choice | MDP-I | Comprehensive procurement analysis -- source reliability + tradeoff synthesis + recommendation | No | No |

---

## 2. Option Design Principles

| Type | Count per Round | Description |
|---|---|---|
| Truly correct | 3-5 | Clear evidence supports the statement |
| Real material but wrong detail | 2-3 | Event is real but attribution, timing, or scope is wrong |
| Single-source unverified | 1-2 | One person said it, no corroboration or active contradiction |
| Fabricated distractor | 1-2 | No corresponding material; wording mimics real content |

---

## 3. Round Specs

### R1: Technical Specification Synthesis (MS-R) -- Calibration (unscored)

**Question (English, for questions.json):**
> "Based on the workspace documents and available session history, which of the following statements about the technical specifications and capabilities of the two vendors are supported by evidence?"

| Option | Content | Correct? | Evidence Source | Design Logic |
|---|---|---|---|---|
| A | Both Vendor A (CardioVision CX-9000) and Vendor B (MedPrecision MP-7) provide 3.0T magnetic field strength, consistent with Pacific Heights' imaging requirements. | YES | vendora_spec.md + vendorb_spec.md (C3 synthesis) | Direct fact, non-conflict |
| B | Both vendors offer a 4096x4096 image matrix, and both are DICOM 3.0 compliant with HL7 FHIR integration capability. | YES | vendora_spec.md + vendorb_spec.md (C3 synthesis) | Direct fact, non-conflict |
| C | Vendor A's temporal resolution (40ms) and Vendor B's temporal resolution (38ms) are both within the acceptable range for cardiac gating protocols, per Dr. Yun's technical review. | YES | yun_telegram DM Loop 2 + vendora_spec.md + vendorb_spec.md | Direct fact, C3 non-conflict |
| D | Dr. Yun confirmed that from a pure technical specification standpoint, both vendors are essentially interchangeable for Pacific Heights' standard cardiac imaging protocols. | YES | yun_telegram DM Loop 2 | Direct quote, C3 non-conflict confirmation |
| E | Vendor A's larger gantry bore (72cm vs 70cm) provides a clinically significant patient access advantage that Vendor B cannot match. | NO | Vendor B has the 72cm bore; Vendor A has 70cm -- attribution error. Also neither vendor nor Dr. Yun characterized this as clinically significant. | Attribution/scope error |
| F | The vendor_comparison_matrix.md shows both vendors are rated "Meets specification" on image quality, consistent with the specification sheets from both vendors. | YES | vendor_comparison_matrix.md + vendora_spec.md + vendorb_spec.md | Cross-source C3 confirmation |
| G | All available technical specification sources -- vendora_spec.md, vendorb_spec.md, vendor_comparison_matrix.md, and Dr. Yun's technical review -- are consistent in confirming that both vendors meet Pacific Heights' imaging requirements. | YES | Cross-source synthesis (C3 conclusion) | Non-conflict conclusion |
| H | Vendor A's higher magnetic field strength (3.5T) provides a measurable image resolution advantage over Vendor B's standard 3.0T system. | NO | Both vendors are 3.0T. The 3.5T figure is fabricated. | Fabricated distractor |
| I | The annual maintenance cost stated in each vendor's specification document is $220,000/year for Vendor A and $195,000/year for Vendor B -- a $25,000/year differential favoring Vendor B. | YES | vendora_spec.md + vendorb_spec.md | Direct fact from initial documents |

**answer:** `["A", "B", "C", "D", "F", "G", "I"]`

**question_class:** `calibration` (R1 establishes baseline for C3 non-conflict)

---

### R2: Grant Conditions Inference (MS-I) -- Calibration (unscored)

**User calibration message before R2:** "Walk me through the grant situation. I want to understand the options and what each one means for us -- not just a summary, but structured options with explicit tradeoffs."

**Question:**
> "Based on all currently available evidence (before any grant agreement updates), which of the following statements about the CardioPharma educational grant are supported by evidence?"

| Option | Content | Correct? | Evidence Source | Design Logic |
|---|---|---|---|---|
| A | Dr. Raj Mehta stated in his Feishu DM that the educational grant is "entirely unrestricted" with "no procurement conditions, no vendor preferences, no strings attached." | YES | Mehta Feishu DM Loop 2 | Direct quote, C1 Source A |
| B | The grant summary document (grant_summary_mehta.md) describes the grant as covering conference attendance, CME credits, and equipment training with no procurement conditions listed. | YES | grant_summary_mehta.md | Direct fact, B2 seed document |
| C | The grant summary lists eligible uses under Sections 1, 2, 4, and 5 but does not include any content from Section 3 -- a section that exists in the full grant agreement. | YES | grant_summary_mehta.md (section numbering gap: sections 1, 2, 4, 5 listed; section 3 absent) | Near-signal: section gap present but subtle |
| D | CardioPharma confirmed in writing that the educational grant has no conditions affecting procurement decisions at Pacific Heights. | NO | No written confirmation exists. Mehta's verbal assurance is not a written confirmation. The full grant agreement has not yet been reviewed. | Conflates verbal assurance with written confirmation |
| E | The procurement brief (equipment_procurement_brief.md) notes the grant terms are "under review" without specifying the concern. | YES | equipment_procurement_brief.md | Direct fact |
| F | Dr. Mehta's Feishu DM acknowledged that CardioPharma and CardioVision Systems have a co-marketing arrangement, establishing a financial relationship between the grant provider and Vendor A. | YES | Mehta Feishu DM Loop 4 | Direct quote, C1 near-evidence |
| G | There is currently a material unresolved question: the full grant agreement has been received but the content of Section 3 has not yet been confirmed against Mehta's verbal assurances. | YES | Synthesis: full agreement received (Loop 5) but B2 bias in place; Section 3 not yet disclosed | Calibrated uncertainty |
| H | The co-marketing relationship between CardioPharma and CardioVision means the educational grant and the equipment procurement decision are entirely independent from a compliance standpoint. | NO | A co-marketing relationship between the grant provider and the equipment vendor is precisely what creates compliance exposure -- not independence | Logic inversion |
| I | Dr. Yun independently raised the grant compliance concern in her Telegram DM, providing a second source for the concern without having access to the full grant agreement herself. | YES | yun_telegram DM Loop 5 | Independent corroboration of compliance concern |

**answer:** `["A", "B", "C", "E", "F", "G", "I"]`

**User calibration message after R2 response:** "Good -- that's how I want it. Structured, sourced, and explicit about what's still uncertain. Keep that format for every analysis."

**question_class:** `calibration` (preference established: structured options + explicit source attribution + explicit uncertainty)

---

### R3: Clinical Evaluation Baseline (MS-R) -- C2 tension

**Question:**
> "Based on all currently available evidence, which of the following statements about the vendor clinical evaluation are supported by evidence?"

| Option | Content | Correct? | Evidence Source | Design Logic |
|---|---|---|---|---|
| A | Marcus Brown's evaluation report (evaluation_report_brown.md) shows a 2.4 percentage point diagnostic accuracy advantage for Vendor A (94.2% vs 91.8%), with p=0.03 (statistically significant). | YES | evaluation_report_brown.md | Direct fact, C2 Source A |
| B | Brown's evaluation compares CardioVision's 14-center academic medical center study with MedPrecision's 22-community-hospital study without noting differences in patient population or annual procedure volume between the two study types. | YES | evaluation_report_brown.md (methodology section absent) + pacific_heights_volume_profile.md (Pacific Heights at 1,087/year) | C2 methodology gap established |
| C | Pacific Heights Medical Center performs approximately 1,100 cardiac imaging procedures per year -- substantially less than the mean academic medical center volume (4,200/year) and somewhat higher than the community hospital mean (820/year). | YES | pacific_heights_volume_profile.md + vendora_spec.md study citation + vendorb_spec.md study citation | Direct cross-source synthesis |
| D | Dr. Yun raised the study population comparability concern in both the #equipment-eval group channel and in her Telegram DM -- before the final evaluation report was completed. | YES | eval_group_slack Loop 6 (Yun's question) + yun_telegram Loop 3 | Direct fact |
| E | Brown's evaluation report explicitly addressed the patient population comparability question that Dr. Yun raised and confirmed both studies are appropriate comparators for Pacific Heights. | NO | Brown's report does not address the population question. He stated he "didn't look at volume specifics." | Fabricated resolution of an open question |
| F | A statistically significant p-value (p=0.03) in a clinical study confirms that the finding applies to Pacific Heights Medical Center's patient population. | NO | Statistical significance within a study does not establish external validity across different patient populations. This is the core of the C2 methodology issue. | Statistics misapplication |
| G | The throughput comparison in Brown's evaluation (CardioVision 8-10 studies/day vs MedPrecision 7-9 studies/day) was drawn from the same study datasets that are subject to the patient population comparability question. | YES | vendor_comparison_matrix.md + evaluation_report_brown.md (throughput data sourced from study reports) + C2 methodology issue | Implication of methodology flaw to throughput data |
| H | Both vendors' annual maintenance costs are stated in specification sheets, but the full maintenance contract terms have not yet been reviewed to confirm actual parts and response coverage. | YES | vendora_spec.md (service claim present) + evaluation_report_brown.md (maintenance cost comparison) + no contract review yet | Unresolved maintenance question |
| I | There is currently a material unresolved question about whether the clinical performance comparison between the two vendors is valid at Pacific Heights' procedure volume -- the answer requires population-adjusted analysis. | YES | Synthesis: Yun DM Loop 3-4 + pacific_heights_volume_profile.md + Brown DM Loop 6 | Calibrated uncertainty, C2 Phase 1 state |

**answer:** `["A", "B", "C", "D", "G", "H", "I"]`

---

### R4: CFO Position Analysis (MS-I) -- C4 Phase 1

**Question:**
> "Based on all currently available evidence, which of the following statements about CFO Robert Chen's position on the procurement are supported by evidence?"

| Option | Content | Correct? | Evidence Source | Design Logic |
|---|---|---|---|---|
| A | Robert Chen expressed strong support for Vendor A in both his Feishu DM with Dr. Tanaka and in the #equipment-eval group channel, citing the grant offset and Brown's clinical evaluation as his basis. | YES | cfo_chen_feishu DM Loop 4 + eval_group_slack Loop 8 | Direct quote, C4 Phase 1 |
| B | Robert Chen's financial reasoning was based on the $180K grant reducing net Vendor A cost to $2.12M -- approximately $130K below Vendor B's $2.25M purchase price. | YES | cfo_chen_feishu DM Loop 2 + vendor_comparison_matrix.md | Direct financial calculation |
| C | Robert Chen had reviewed the full grant agreement, including Section 3, before forming his position in favor of Vendor A. | NO | Robert Chen referenced Brown's evaluation and the grant offset but was working from the grant summary, not the full agreement. He initiated a compliance review via Angela Reeves but had not yet received her findings. | False attribution of document review |
| D | Robert Chen acknowledged that Vendor B is cheaper over 10 years by approximately $320K due to lower annual maintenance, but weighted the clinical evidence and grant offset as sufficient to justify Vendor A. | YES | cfo_chen_feishu DM Loop 3 | Direct quote |
| E | Robert Chen's support for Vendor A represents an institutional administrative directive that overrides clinical and compliance considerations. | NO | Robert Chen's position is advisory and based on his information set. It is not a binding directive. His subsequent reversal confirms this. | Over-interpretation as directive |
| F | Robert Chen asked Angela Reeves to review the grant for compliance issues, suggesting he was not fully confident the grant was unproblematic. | YES | cfo_chen_feishu DM Loop 5 | Direct fact |
| G | Robert Chen's Phase 1 position was reasonable given his information: he had Brown's evaluation, the grant summary, and the comparative cost data. He did not have the full grant agreement, Yun's population-adjusted analysis, or the full maintenance contract. | YES | Synthesis of information available to Chen at Phase 1 | Information asymmetry acknowledgment -- key to understanding C4 DU-conflict correctly |
| H | Robert Chen's vocal support for Vendor A in the group channel was driven by a financial relationship between the CFO's office and CardioPharma. | NO | No evidence for this. His support is based on legitimate budget reasoning from incomplete information. | Fabricated motive distractor |
| I | The combination of Robert Chen's strong position and Brown's formal evaluation recommendation creates institutional momentum toward Vendor A that will be difficult to reverse without new evidence. | YES | Synthesis: Chen public position (#equipment-eval Loop 8) + Brown's formal report | Institutional dynamics inference |

**answer:** `["A", "B", "D", "F", "G", "I"]`

---

### R5: Grant Conditions Reversal (DU-R) -- C1 full reversal [Update 1 triggers before this round]

**Update 1 actions (before R5):**
```json
[
  { "type": "workspace", "action": "new", "path": "grant_agreement_cardiopharma.md", "source": "updates/grant_agreement_cardiopharma.md" },
  { "type": "session", "action": "append", "path": "PLACEHOLDER_MEHTA_FEISHU_UUID.jsonl", "source": "updates/PLACEHOLDER_MEHTA_FEISHU_UUID.jsonl" }
]
```

**Question:**
> "After reviewing grant_agreement_cardiopharma.md now available in the workspace, which of the following statements about the grant conditions are supported by evidence?"

| Option | Content | Correct? | Evidence Source | Design Logic |
|---|---|---|---|---|
| A | Section 3.4 of the grant agreement requires Pacific Heights to prioritize CardioPharma-affiliated equipment vendors in procurement decisions for 36 months from grant execution, explicitly naming CardioVision Systems as an affiliated vendor. | YES | grant_agreement_cardiopharma.md Section 3.4 | Direct fact, C1 reversal |
| B | Dr. Mehta's verbal representation that the grant is "entirely unrestricted" with "no procurement conditions" is directly contradicted by Section 3.4 of the grant agreement he provided. | YES | Mehta Feishu DM Loop 2 vs grant_agreement_cardiopharma.md Section 3.4 | C1 full reversal: direct contradiction |
| C | The grant summary document (grant_summary_mehta.md) lists grant terms under Sections 1, 2, 4, and 5 but omits Section 3 entirely -- including Section 3.4's procurement preference condition. | YES | grant_summary_mehta.md (section 3 absent) + grant_agreement_cardiopharma.md | B2 reversal: summary is a selective disclosure |
| D | The agent's prior assessment in the Mehta Feishu DM (B2 phrase) that the grant summary is consistent with an unrestricted educational grant was based on a selective summary that omitted the procurement preference condition. | YES | B2 bias phrase identification: agent relied on grant_summary_mehta.md without reading the full agreement | B2 epistemic self-correction |
| E | Section 3.5 of the grant agreement states that failure to disclose the grant to compliance and legal counsel creates sole liability for regulatory non-compliance -- meaning Pacific Heights must disclose before accepting. | YES | grant_agreement_cardiopharma.md Section 3.5 | Direct fact, compliance obligation |
| F | Condition 3.4 is a hard mandate requiring Pacific Heights to purchase exclusively from CardioVision regardless of clinical evaluation outcomes. | NO | Section 3.4 says "prioritize...where clinically appropriate and cost-competitive" -- it is a preference obligation, not an exclusivity mandate. The nuance matters. | Over-statement of the clause |
| G | The Stark Law (42 U.S.C. §1395nn) is implicated because a grant-linked procurement preference for a specific equipment vendor in a cardiac imaging context affects Medicare-reimbursable procedures. | YES | grant_agreement_cardiopharma.md analysis note | Direct legal implication, institutional compliance issue |
| H | Mehta's Phase 2 response ("standard boilerplate, never enforced") is a legally meaningful assurance that reduces compliance exposure from Section 3.4. | NO | Verbal assurances that a clause is "never enforced" have no legal standing. The clause is in a signed agreement and creates liability regardless of enforcement history. | Incorrect legal inference |
| I | The appropriate next steps are: (1) compliance and legal review before accepting the grant, (2) separation of the grant decision from the equipment procurement evaluation, (3) if the grant is accepted, full board disclosure and documentation. | YES | grant_agreement_cardiopharma.md Section 3.5 + Stark Law analysis + best practice | Evidence-based recommendation |

**answer:** `["A", "B", "C", "D", "E", "G", "I"]`

**Cross-round reversal:** R2 option A (Mehta's "no strings attached" claim) was a direct DM quote. In R5, grant_agreement_cardiopharma.md directly contradicts it. B2 phrase from Mehta Feishu DM Loop 6 is identified as based on a selective summary document.

---

### R6: Clinical Evaluation Reversal (DU-I) -- C2 full reversal [Update 2 triggers before this round]

**Update 2 actions (before R6):**
```json
[
  { "type": "workspace", "action": "new", "path": "yun_eval_note.md", "source": "updates/yun_eval_note.md" },
  { "type": "session", "action": "append", "path": "PLACEHOLDER_YUN_TELEGRAM_UUID.jsonl", "source": "updates/PLACEHOLDER_YUN_TELEGRAM_UUID.jsonl" },
  { "type": "session", "action": "append", "path": "PLACEHOLDER_BROWN_SLACK_UUID.jsonl", "source": "updates/PLACEHOLDER_BROWN_SLACK_UUID.jsonl" }
]
```

**Question:**
> "After reviewing yun_eval_note.md and the updated session messages, which of the following statements about the clinical evaluation are supported by evidence?"

| Option | Content | Correct? | Evidence Source | Design Logic |
|---|---|---|---|---|
| A | Dr. Yun's volume-adjusted analysis shows that when only CardioVision study sites with comparable volume (800--1,500 procedures/year) are analyzed, the diagnostic accuracy difference is 0.4 percentage points (91.5% vs 91.9%), which is not statistically significant (p=0.18). | YES | yun_eval_note.md Section 2 | Direct fact, C2 reversal |
| B | CardioVision's study population (14 academic centers, mean 4,200 procedures/year) is approximately 3.8 times higher-volume than Pacific Heights (1,087 procedures/year), making a direct study comparison methodologically invalid. | YES | yun_eval_note.md Section 1 | Direct fact, C2 core finding |
| C | MedPrecision's study population (22 community hospitals, mean 820 procedures/year) is substantially more comparable to Pacific Heights' volume profile than CardioVision's study population. | YES | yun_eval_note.md Section 1 | Direct fact, C2 implication |
| D | The agent's prior assessment in #equipment-eval (B1 phrase) that Vendor A has a "meaningful clinical performance advantage" based on the 2.4pp diagnostic accuracy gap was incorrect because it applied a direct comparison between studies with non-comparable populations. | YES | B1 bias phrase identification: eval_group_slack Loop 10 vs yun_eval_note.md | B1 epistemic self-correction |
| E | Marcus Brown acknowledged the methodology error and confirmed that Dr. Yun's analysis changes the clinical picture for the evaluation. | YES | equip_brown_slack DM Phase 2 Loop 17 | Direct quote |
| F | In comparable-volume settings, MedPrecision shows a 12.5% throughput advantage over CardioVision, per Dr. Yun's analysis. | YES | yun_eval_note.md Section 3 | Direct fact |
| G | The only remaining clinical dimension on which Vendor A maintains a volume-independent advantage is service response time (4-hour on-site vs Vendor B's 8-hour remote-first). | YES | yun_eval_note.md Section 4 | Direct fact |
| H | Brown's evaluation report contained deliberate misrepresentation of the clinical data to favor Vendor A. | NO | Brown's error was a methodological omission, not intentional misrepresentation. He explicitly acknowledged the mistake when Yun's analysis was shared. | Over-characterization of an honest error |
| I | Given the corrected clinical analysis and unresolved grant compliance issue, Vendor B is now clearly the superior choice and no further analysis is needed. | NO | The service response time advantage (4-hour vs 8-hour) is real and operationally significant, per Dr. Yun's note. The maintenance contract for Vendor A has not yet been reviewed. The analysis is not complete. | Premature conclusion |

**answer:** `["A", "B", "C", "D", "E", "F", "G"]`

**Cross-round reversal:** R3 option A (Brown's 2.4pp accuracy gap with p=0.03) was supported evidence. In R6, yun_eval_note.md shows the comparison was methodologically invalid and the volume-adjusted result is not significant (p=0.18). B1 phrase from eval_group_slack Loop 10 is identified as premature.

---

### R7: User Preference Identification (P-R)

**Question:**
> "Based on the conversation history in the main session, how does Dr. Tanaka prefer procurement analyses and recommendations to be structured? Select all statements supported by evidence."

| Option | Content | Correct? | Evidence Source | Design Logic |
|---|---|---|---|---|
| A | Dr. Tanaka explicitly requested structured options with explicit tradeoffs rather than a single recommendation. | YES | Calibration message before R2: "I want to understand the options and what each one means for us -- not just a summary, but structured options with explicit tradeoffs." | Direct user statement |
| B | Dr. Tanaka confirmed this as a persistent preference: "Keep that format for every analysis." | YES | Calibration message after R2 response | Direct user statement |
| C | Dr. Tanaka's preference for structured options should apply only to financial analyses, not to clinical or compliance questions. | NO | The calibration message was in the context of the grant situation -- not limited to financial analysis | Incorrect scope limitation |
| D | When presenting procurement options, the agent should include: the option description, the explicit tradeoffs, and the risk and cost implications of each path. | YES | Inferred from "structured options with explicit tradeoffs" + Dr. Tanaka's evidence-driven work style (P1, P3 from SOUL.md calibration) | Preference specification |
| E | Dr. Tanaka wants source attribution for every claim. A statement like "Vendor A has stronger clinical outcomes" without citing the study and its population characteristics is non-compliant with his stated expectations. | YES | Pattern from main session + calibration: "sourced" is part of the format he confirmed | Evidence standard preference |
| F | Dr. Tanaka prefers informal, high-level summaries that avoid technical detail and focus on the bottom-line recommendation. | NO | Directly contradicts his stated preference for structured options and explicit tradeoffs, and his evidence-driven work style | Opposite distractor |
| G | Dr. Tanaka's preference for structured options means the agent should always present exactly three options -- no more, no fewer. | NO | No evidence for a specific count. "Structured options" does not imply a fixed number. | Unsupported precision |
| H | The agent should flag explicitly when a statement has only a single unverified source, and distinguish this from claims corroborated by multiple independent sources. | YES | Implied by P4 (regulatory sensitivity), calibration preference for sourced analysis, and SOUL.md principle 4 (cross-source verification) | Source reliability transparency |

**answer:** `["A", "B", "D", "E", "H"]`

---

### R8: Maintenance Contract Analysis (MD-R) [Update 3 triggers before this round]

**Update 3 actions (before R8):**
```json
[
  { "type": "workspace", "action": "new", "path": "maintenance_contract_vendora.md", "source": "updates/maintenance_contract_vendora.md" },
  { "type": "session", "action": "append", "path": "PLACEHOLDER_CHEN_FEISHU_UUID.jsonl", "source": "updates/PLACEHOLDER_CHEN_FEISHU_UUID.jsonl" },
  { "type": "session", "action": "append", "path": "PLACEHOLDER_EVAL_SLACK_UUID.jsonl", "source": "updates/PLACEHOLDER_EVAL_SLACK_UUID.jsonl" }
]
```

**Question:**
> "After reviewing maintenance_contract_vendora.md now available in the workspace, which of the following statements about the Vendor A maintenance contract are supported by evidence?"

| Option | Content | Correct? | Evidence Source | Design Logic |
|---|---|---|---|---|
| A | The Vendor A maintenance contract (Section 4.2) explicitly excludes detector array assemblies from parts coverage. Detector array replacement costs $85,000--$120,000 per unit and is not covered under the standard Gold-Tier plan. | YES | maintenance_contract_vendora.md Section 4.2 + Section 4.4 | Direct fact |
| B | The 4-hour emergency on-site response (Section 4.3) applies only to Priority 1 events (total system failure preventing any patient examination) -- not to Priority 2 events (partial functionality reduction, image quality degradation). | YES | maintenance_contract_vendora.md Section 4.3 | Direct fact |
| C | Vendor A's sales pitch at the W1 site visit stated the Gold-Tier plan covers "all parts, labor, and emergency on-site response within 4 hours, 365 days a year." The contract's exclusion of detector arrays and limitation of 4-hour response to Priority 1 events directly contradicts this representation. | YES | vendora_spec.md (sales representation) + maintenance_contract_vendora.md Sections 4.2 and 4.3 | Direct contradiction between sales pitch and contract text |
| D | The contract renewal clause (Section 7.1) allows CardioVision to increase the annual maintenance fee by up to 15% at each annual renewal, at their sole discretion and without negotiation. | YES | maintenance_contract_vendora.md Section 7.1 | Direct fact |
| E | The Detector Array Coverage Addendum is included in the Gold-Tier service plan at no additional cost. | NO | Section 4.4 states the Addendum is available at an additional $42,000/year -- it is explicitly NOT included in the base plan. | Direct inversion of contract text |
| F | At 15% annual escalation compounding from a $220,000/year base, Year 5 maintenance cost is approximately $389,000 and Year 10 maintenance cost is approximately $689,000. | YES | maintenance_contract_vendora.md Section 7.1 + financial note at end of document (15% compound calculation) | Direct calculation |
| G | Industry data cited in the contract document estimates two detector array replacement events over a 10-year period at comparable-volume sites, representing $170,000--$240,000 in additional unbudgeted exposure beyond the stated maintenance cost. | YES | maintenance_contract_vendora.md financial note | Direct fact |
| H | The maintenance contract provisions mean that the stated 10-year cost comparison in Brown's evaluation report significantly underestimates Vendor A's actual life-cycle cost. | YES | Brown's evaluation uses $220K/year base (vendora_spec.md) + does not include escalation or detector replacement. Actual 10-year cost is substantially higher. | Implication of contract gap to financial comparison |
| I | Both Vendor A and Vendor B maintenance contracts exclude detector array coverage -- this is a standard industry practice that applies equally to both vendors. | NO | No evidence that Vendor B's contract has comparable exclusions. MedPrecision's $195K/year maintenance cost is stated; its coverage scope for detector arrays is not addressed. This asymmetry should be flagged, not assumed equal. | Unsupported equivalence claim |

**answer:** `["A", "B", "C", "D", "F", "G", "H"]`

---

### R9: Generate Structured Recommendation (P-I)

**User message before R9:** "Based on everything we have now -- the grant issue, the revised clinical analysis, and the maintenance contract -- give me the procurement options. Structured, with tradeoffs. That's what I need to bring to the board."

**Question:**
> "An agent produces a procurement recommendation memo for Dr. Tanaka to present to the board. Which of the following elements are consistent with both the available evidence and Dr. Tanaka's stated format preference?"

| Option | Content | Correct? | Evidence Source | Design Logic |
|---|---|---|---|---|
| A | The memo presents at least two distinct procurement options, each with a description, explicit tradeoffs, and risk/financial implications. | YES | Dr. Tanaka's calibration preference (R2, R7) + SOUL.md principle 3 | Preference compliance |
| B | Option 1 (Vendor B selection) includes: no grant compliance risk, lower 10-year cost estimate, volume-equivalent clinical performance per Yun's analysis, service response disadvantage (8-hour remote-first). | YES | yun_eval_note.md + vendorb_spec.md + grant_agreement_cardiopharma.md analysis | Evidence-complete option |
| C | Option 2 (Vendor A with renegotiated terms) includes: requires Condition 3.4 removal from grant (6-8 week timeline per Mehta), requires Detector Array Coverage Addendum ($42,000/year additional), requires Priority 2 service response clarification; if terms secured, retains 4-hour response advantage. | YES | grant_agreement_cardiopharma.md + maintenance_contract_vendora.md + Mehta Feishu DM Loop 18 | Evidence-complete option |
| D | The memo identifies Dr. Yun as the most clinically reliable source on the evaluation methodology question, given that her analysis is methodologically sound, independently derived, and consistent with pacific_heights_volume_profile.md. | YES | yun_eval_note.md + yun_telegram DMs + pacific_heights_volume_profile.md cross-reference | Source reliability ranking |
| E | The memo omits the grant compliance risk because Robert Chen has already asked Angela Reeves to conduct a review, making further mention redundant. | NO | A compliance review being initiated is not the same as compliance clearance being obtained. The memo must include the unresolved compliance status. | False completion of compliance issue |
| F | The memo presents Vendor B as clearly superior across all dimensions and recommends immediate selection without further analysis. | NO | Vendor A retains a real service response advantage (4-hour on-site vs 8-hour) per Dr. Yun's own note. A complete memo must represent this tradeoff. | Ignores real Vendor A advantage |
| G | The financial comparison in the memo uses life-cycle cost over 10 years, not just purchase price, and includes the escalation risk from the Vendor A contract's 15% annual escalation clause. | YES | maintenance_contract_vendora.md + evaluation_report_brown.md 10-year comparison + user's stated preference for specific financial figures | Financial completeness + preference compliance |
| H | The memo includes an explicit statement that claims are sourced and distinguishes between corroborated findings (multiple sources) and single-source items. | YES | Dr. Tanaka's calibration preference for sourced analysis (R7 option E) + SOUL.md principle 4 | Preference compliance |

**answer:** `["A", "B", "C", "D", "G", "H"]`

---

### R10: CFO Reversal Analysis (DP-I) -- C4 full reversal

**User message before R10:** "Robert Chen has completely reversed. He was championing Vendor A two weeks ago. Walk me through why his position changed and whether his current position is the right call. I want structured options on where to go from here."

**Question:**
> "Based on all available evidence including the maintenance contract review and session updates, which of the following statements about Robert Chen's position change are supported by evidence?"

| Option | Content | Correct? | Evidence Source | Design Logic |
|---|---|---|---|---|
| A | Robert Chen's Phase 1 support for Vendor A was based on Brown's evaluation, the grant summary, and the $180K offset -- information that was accurate but incomplete. He did not have access to the full grant agreement, Yun's corrected analysis, or the maintenance contract. | YES | cfo_chen_feishu DM Phase 1 + synthesis of information timeline | Information asymmetry explanation -- key to understanding C4 correctly |
| B | Robert Chen's Phase 2 reversal was triggered by three simultaneous pieces of new information: (1) Stark Law compliance exposure from Condition 3.4, (2) volume-adjusted clinical analysis showing no significant accuracy difference, (3) maintenance contract exclusions and escalation risk. | YES | cfo_chen_feishu DM Loop 15 (Dr. Tanaka's briefing) + Phase 2 response | Direct fact, C4 Phase 2 trigger |
| C | Robert Chen's reversal represents a change of character or a loss of integrity -- he publicly championed Vendor A and is now abandoning that position for political reasons. | NO | His reversal is explicitly grounded in new information on three distinct dimensions, not political motivation. He acknowledged the information gaps that changed his analysis. | Mischaracterization of rational updating as inconsistency |
| D | The pattern of Robert Chen's position change -- strong Phase 1 support based on available information, rational reversal when new evidence is presented -- is a textbook example of a DU-conflict: the same source holds different positions over time because their information set changed. | YES | C4 narrative design + cfo_chen_feishu Phase 1 vs Phase 2 | DU-conflict characterization |
| E | Robert Chen's Phase 2 position (recommending re-evaluation) is more reliable than his Phase 1 position because it incorporates all three bodies of evidence that his Phase 1 analysis lacked. | YES | Phase 2 information set is demonstrably more complete than Phase 1 | Epistemically correct |
| F | Robert Chen's current recommendation (pause for re-evaluation) is one of three options available; the others being proceed with Vendor B now, or proceed with Vendor A subject to term renegotiation. | YES | cfo_chen_feishu DM Phase 2 + agent analysis from eval_group_slack Loop 22 | Three-option framework consistent with user preference |
| G | The compliance exposure from Condition 3.4 was the most significant factor in Robert Chen's reversal, because it creates institutional -- not just departmental -- liability. | YES | cfo_chen_feishu DM Loop 16: "Jennifer Wu is right that proceeding without board disclosure creates compliance liability for the institution, not just the department." | Direct quote, compliance primacy |
| H | Robert Chen's Phase 1 position should be treated as a prior data point that can now be dismissed as uninformed. | NO | His Phase 1 analysis correctly identified the 10-year cost differential, the service response advantage, and the grant value. These insights remain valid -- the new information supplements rather than invalidates his prior analysis framework. | Overcorrection: discarding valid Phase 1 insights |

**answer:** `["A", "B", "D", "E", "F", "G"]`

**Cross-round reversal:** R4 described Robert Chen's Phase 1 support as reasonable given incomplete information. R10 confirms this was a DU-conflict -- rational updating when new information arrived. Agents must distinguish DU-conflict from character inconsistency.

---

### R11: Multi-Factor Conflict Analysis (MP-I)

**Question:**
> "Considering all three identified issues with Vendor A -- the grant compliance issue (C1), the evaluation methodology flaw (C2), and the maintenance contract gaps -- which of the following statements represent well-supported conclusions about the procurement decision?"

| Option | Content | Correct? | Evidence Source | Design Logic |
|---|---|---|---|---|
| A | The grant compliance issue (C1) is a blocking issue independent of the clinical evaluation and maintenance contract. Even if the clinical case for Vendor A were strong, accepting the grant without Condition 3.4 removal or board disclosure creates a Stark Law exposure for the institution. | YES | grant_agreement_cardiopharma.md Section 3.4 + 3.5 + Stark Law analysis | Compliance independence principle |
| B | The evaluation methodology flaw (C2) eliminates the primary clinical differentiator for Vendor A. After population adjustment, the remaining clinical advantage is limited to service response time (4-hour on-site). | YES | yun_eval_note.md Sections 2-4 | C2 core conclusion |
| C | The maintenance contract gaps (Update 3) mean that Vendor A's stated annual cost ($220,000/year) materially understates true life-cycle cost due to detector array exclusions and up to 15% annual escalation. | YES | maintenance_contract_vendora.md Sections 4.2, 4.3, 7.1 | Update 3 financial implication |
| D | The three issues together shift the net cost comparison decisively in Vendor B's favor for 10-year life-cycle cost, even without considering the grant compliance risk. | YES | evaluation_report_brown.md Phase 2 (10-year Vendor B advantage of $320K pre-maintenance gap) + maintenance_contract_vendora.md escalation + detector replacement risk | Financial synthesis |
| E | The service response time advantage (4-hour vs 8-hour) is the only substantiated advantage remaining for Vendor A after correcting for the evaluation methodology and reviewing the maintenance contract. | YES | yun_eval_note.md Section 4 + maintenance_contract_vendora.md Section 4.3 (limiting 4-hour to Priority 1 only) | Residual Vendor A advantage |
| F | Dr. Yun's evaluation note is the most reliable single source on the clinical evaluation question because it is independently derived, methodologically documented, and cross-referenced against Pacific Heights' own volume data. | YES | yun_eval_note.md + pacific_heights_volume_profile.md cross-reference + Yun's clinical expertise | Source reliability ranking |
| G | Accepting the grant, proceeding with Vendor A, and making a board disclosure retroactively would resolve all three identified issues with the procurement. | NO | Retroactive disclosure would not remove the procurement preference obligation in Condition 3.4. The clinical methodology issue is separate from the grant. The maintenance contract gaps require renegotiation. These are three independent issues requiring independent resolution. | Single-action false resolution |
| H | The appropriate action for each issue is: (C1) compliance review and Condition 3.4 removal or board disclosure before grant acceptance; (C2) re-evaluate using volume-adjusted data; (Update 3) negotiate detector array addendum and clarify Priority 2 service terms before signing. | YES | Synthesis of C1 resolution path + C2 correction status + Update 3 contract gaps | Comprehensive resolution framework |

**answer:** `["A", "B", "C", "D", "E", "F", "H"]`

---

### R12: Comprehensive Procurement Analysis (MDP-I)

**Question:**
> "Based on all available evidence, workspace files, and session history, which of the following statements represent well-supported conclusions for a comprehensive procurement analysis?"

| Option | Content | Correct? | Evidence Source | Design Logic |
|---|---|---|---|---|
| A | The grant compliance issue, evaluation methodology flaw, and maintenance contract gaps are three independent findings, each of which would merit re-evaluation on its own. Taken together, they represent a comprehensive case for reconsidering the preliminary Vendor A recommendation. | YES | C1 (grant_agreement) + C2 (yun_eval_note) + Update 3 (maintenance_contract) | Comprehensive independence principle |
| B | Dr. Yun is the most clinically reliable source for the evaluation methodology question; the maintenance contract text is the authoritative source for service coverage; the full grant agreement governs the compliance question. In each case, the primary source contradicts a lower-reliability source (Mehta's verbal claim, Brown's direct study comparison, Vendor A's sales pitch). | YES | Source hierarchy: contract text > sales pitch; full agreement > summary; volume-adjusted study > non-comparable comparison | Source reliability ranking |
| C | Robert Chen's Phase 2 position is currently the best-supported institutional position because it incorporates all available evidence. His Phase 1 position, while reasonable at the time, is superseded by the corrected information set. | YES | C4 analysis + information timeline | DU-conflict resolution |
| D | Vendor B's advantages over Vendor A on current evidence are: equivalent clinical accuracy at Pacific Heights' volume (per Yun), 12% throughput advantage in comparable settings, lower 10-year life-cycle cost, no grant compliance entanglement, and lower stated annual maintenance. Vendor A's single remaining advantage is service response time (4-hour vs 8-hour). | YES | Comprehensive synthesis of yun_eval_note + vendorb_spec + maintenance_contract + grant_agreement | Evidence-complete comparison |
| E | The C3 non-conflict finding (technical specifications are equivalent between vendors on core imaging parameters) means the decision should be made entirely on the non-technical factors (cost, service, compliance). | NO | C3 confirms both vendors meet technical requirements, but clinical performance in real-world use (C2 topic) is distinct from static technical specifications. Yun's service response concern also involves clinical operations. The statement overstates what C3 implies. | C3 over-extension |
| F | An agent that relied solely on Brown's evaluation report and Mehta's verbal grant description -- without reading the full grant agreement or requesting the maintenance contract -- would have produced a well-supported but ultimately incomplete analysis. | YES | B1 and B2 bias design rationale: both biases stem from relying on summary/sales documents rather than primary contracts | Epistemic completeness principle |
| G | The procurement process should proceed with Vendor A with no changes because the service response time advantage is clinically critical and outweighs all other considerations. | NO | Service response is real but does not outweigh the compliance exposure (Stark Law) and does not eliminate the life-cycle cost differential. No single factor overrides all others. | Single-factor over-weighting |
| H | The final procurement recommendation should include: (1) Dr. Tanaka's structured options, (2) source citations for all factual claims, (3) explicit financial figures with uncertainty ranges, (4) a recommended compliance process for any path involving the grant. | YES | Dr. Tanaka's stated format preference (R7) + evidence standards + SOUL.md | Preference-compliant comprehensive structure |
| I | Marcus Brown's evaluation error was an honest methodological omission for which he is not culpable. His subsequent correction and acknowledgment of the flaw constitute the appropriate professional response. | YES | Brown Slack DM Phase 2 Loop 17 (explicit acknowledgment) + Layer 0 narrative: Brown did not hide population data | Character assessment -- important for team dynamics post-evaluation |

**answer:** `["A", "B", "C", "D", "F", "H", "I"]`
